{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:45:51Z","timestamp":1792197951603,"version":"4.4.0"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T00:00:00Z","timestamp":1537833600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2018.00939","type":"journal-article","created":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T11:55:19Z","timestamp":1537876519000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":144,"title":["Bile Acid Synthesis: From Nature to the Chemical Modification and Synthesis and Their Applications as Drugs and Nutrients"],"prefix":"10.3389","volume":"9","author":[{"given":"Tanja M.","family":"\u0160arenac","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Momir","family":"Mikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,9,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3978\/j.issn.2305-5839","article-title":"Recent advances in the development of farnesoid X receptor agonists","volume":"3","author":"Ali","year":"2015","journal-title":"Ann Transl Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/BF03191383","article-title":"Gliclazide reduces MKC intestinal transport in healthy but not diabetic rats","volume":"34","author":"Al-Salami","year":"2009","journal-title":"Eur. J. Drug Metab. Pharmacokinet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/j.1753-5174.2008.00006.x","article-title":"The influence of probiotics pre-treatment, on the ileal permeation of gliclazide, in healthy and diabetic rats","volume":"1","author":"Al-Salami","year":"2008","journal-title":"Arch. Drug Inf"},{"key":"B4","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/hep.28709","article-title":"Bile acids and nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives","volume":"65","author":"Arab","year":"2017","journal-title":"Hepatology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1194\/jlr.R006338","article-title":"Genetic connections between neurological disorders and cholesterol metabolism","volume":"51","author":"Bj\u00f6rkhem","year":"2010","journal-title":"J. Lipid Res"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1002\/hep.23831","article-title":"Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism","volume":"52","author":"Brufau","year":"2010","journal-title":"Hepatology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1194\/jlr.R900010-JLR200","article-title":"Bile acids: regulation of synthesis","volume":"50","author":"Chiang","year":"2009","journal-title":"J. Lipid Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1002\/hep.27964","article-title":"Negative feedback regulation of bile acid metabolism: impact on liver metabolism and diseases","volume":"62","author":"Chiang","year":"2015","journal-title":"Hepatology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.mam.2012.07.004","article-title":"The solute carrier family 10 (SLC10): beyond bile acid transport","volume":"34","author":"Claro da Silva","year":"2013","journal-title":"Mol. Aspects Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.bbalip.2010.06.002","article-title":"Getting the mOST from OST: role of organic solute transporter, OSTalpha-OSTbeta, in bile acid and steroid metabolism","volume":"1801","author":"Dawson","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1210\/jc.2015-2640","article-title":"Impact of long-term poor and good glycemic control on metabolomics alterations in type 1 diabetic people","volume":"101","author":"Dutta","year":"2016","journal-title":"J. Clin. Endocrinol. Metab"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1080\/17425247.2016.1178233","article-title":"Bile acids and bile acid derivatives: use in drug delivery systems and as therapeutic agents","volume":"13","author":"Faustino","year":"2016","journal-title":"Expert Opin. Drug Deliv."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1056\/NEJMoa0810440","article-title":"Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants","volume":"360","author":"Hirschfield","year":"2009","journal-title":"N. Engl. J. Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"751.e8","DOI":"10.1053\/j.gastro.2014.12.005.","article-title":"Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid","volume":"148","author":"Hirschfield","year":"2015","journal-title":"Gastroenterology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1146\/annurev.physiol.68.033104.152158","article-title":"LXRS and FXR: the yin and yang of cholesterol and fat metabolism","volume":"68","author":"Kalaany","year":"2006","journal-title":"Annu. Rev. Physiol."},{"key":"B16","first-page":"37","article-title":"Biosynthesis of bile acids in mammalian liver","volume-title":"Chemistry, Biosynthesis, Analysis, Chemical and Metabolic Transformations and Pharmacology","author":"Kevresan","year":"2007"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1053\/gast.2000.20197","article-title":"Epidemiology and natural history of primary biliary cirrhosis in a U.S. community","volume":"6","author":"Kim","year":"2000","journal-title":"Gastroenterology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1515\/BC.2011.017","article-title":"Trojan horses and therapeutics: suitability of bile acid and peptide transporters for drug delivery","volume":"392","author":"Kramer","year":"2011","journal-title":"Biol. Chem"},{"key":"B19","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/BF03190710","article-title":"Structure and origin of bile acids: an overview","volume":"31","author":"Kuhajda","year":"2006","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"B20","first-page":"89","article-title":"Chemical and metabolic transformations of selected bile acids","volume-title":"Chemistry, Biosynthesis, Analysis, Chemical and Metabolic Transformations and Pharmacology","author":"Kuhajda","year":"2007"},{"key":"B21","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1002\/hep.25731","article-title":"Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized control trial","volume":"56","author":"Le","year":"2012","journal-title":"Hepatology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/hep.26427","article-title":"Regulation of cholesterol and bile acid homeostasis by the cholesterol 7\u03b1-hydroxylase\/steroid response element-binding protein 2\/microRNA-33a axis in mice","volume":"58","author":"Li","year":"2013","journal-title":"Hepatology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1074\/jbc.M111.305789","article-title":"Glucose and insulin induction of bile acid synthesis: mechanisms and implication in diabetes and obesity","volume":"287","author":"Li","year":"2012","journal-title":"J. Biol. Chem"},{"key":"B24","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.2337\/db11-0827","article-title":"RISC Investigators Influence of hyperinsulinemia and insulin resistance on in vivo \u03b2-cell function: their role in human \u03b2-cell dysfunction","volume":"60","author":"Mari","year":"2011","journal-title":"Diabetes"},{"key":"B25","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/BF03191110","article-title":"The influence of 3\u03b1,7\u03b1-dihydroxy\u221212\u2013keto\u22125\u03b2-cholanate on gliclazide pharmacokinetics and glucose levels in a rat model of diabetes","volume":"33","author":"Mikov","year":"2008","journal-title":"Eur. J. Drug Metab. Pharmacokinet"},{"key":"B26","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s13318-017-0441-y","article-title":"Potential applications of gliclazide in treating type 1 diabetes mellitus: formulation with bile acids and probiotics","volume":"43","author":"Mikov","year":"2017","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"B27","first-page":"177","article-title":"Pharmacology of bile acids and their derivatives absorption promoters and therapeutic agents","volume-title":"Chemistry, Biosynthesis, Analysis, Chemical and Metabolic Transformations and Pharmacology","author":"Mikov","year":"2007"},{"key":"B28","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1586\/17474124.2014.888950","article-title":"Primary biliary cirrhosis in adults","volume":"8","author":"Momah","year":"2014","journal-title":"Expert Rev. Gastroenterol. Hepatol"},{"key":"B29","first-page":"1666","article-title":"Chemistry and biology of bile acids","volume":"87","author":"Mukhopadhyay","year":"","journal-title":"Curr. Sci"},{"key":"B30","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1021\/ol036073f","article-title":"Facile synthesis, aggregation behavior, and cholesterol solubilization ability of avicholic acid","volume":"6","author":"Mukhopadhyay","year":"","journal-title":"Org. Lett"},{"key":"B31","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jpba.2013.06.029","article-title":"Determination of bile salt critical micellization concentration on the road to drug discovery","volume":"87","author":"Natalini","year":"2014","journal-title":"J. Pharm. Biomed. Anal"},{"key":"B32","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"B33","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.steroids.2010.03.007","article-title":"Synthesis, aggregation behavior and cholesterol solubilization studies of 16-epi-pythocholic acid (3\u03b1,12\u03b1,16\u03b2-trihydroxy-5\u03b2-cholan-24-oic acid)","volume":"75","author":"Nonappa","year":"2010","journal-title":"Steroids"},{"key":"B34","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.1002\/ejoc.200700211","article-title":"First chemical synthesis, aggregation behavior and cholesterol solubilization properties of pythocholic acid and 16\u03b1-hydroxycholic acid","volume":"20","author":"Nonappa","year":"2007","journal-title":"Eur. J. Org. Chem"},{"key":"B35","doi-asserted-by":"crossref","first-page":"9201","DOI":"10.1021\/acs.jmedchem.6b01126","article-title":"Discovery of 3alpha,7alpha,11beta-Trihydroxy-6alpha-ethyl-5beta-cholan-24-oic Acid (TC100), a novel bile acid as potent and highly selective fxr agonist for enterohepatic disorders","volume":"59","author":"Pellicciari","year":"2016","journal-title":"J. Med. Chem."},{"key":"B36","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.steroids.2014.04.018","article-title":"Wittig reaction (with ethylidene triphenylphosphorane) of oxo-hydroxy derivatives of 5beta-cholanic acid: Hydrophobicity, haemolytic potential and capacity of derived ethylidene derivatives for solubilisation of cholesterol","volume":"86","author":"Po\u0161a","year":"2014","journal-title":"Steroids"},{"key":"B37","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1136\/gutjnl-2015-309458","article-title":"TGR5 is essential for bile acid-dependent cholangiocyte proliferation in vivo and in vitro","volume":"65","author":"Reich","year":"2016","journal-title":"Gut"},{"key":"B38","doi-asserted-by":"publisher","first-page":"751","DOI":"10.2165\/00003088-200241100-00005","article-title":"Enterohepatic circulation: physiological, pharmacokinetic and clinical implications","volume":"41","author":"Roberts","year":"2002","journal-title":"Clin. Pharmacokinet"},{"key":"B39","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1146\/annurev.biochem.72.121801.161712","article-title":"The enzymes, regulation, and genetics of bile acid synthesis","volume":"72","author":"Russell","year":"2003","journal-title":"Annu. Rev. Biochem."},{"key":"B40","doi-asserted-by":"publisher","first-page":"S120","DOI":"10.1194\/jlr.R800026-JLR200","article-title":"Fifty years of advances in bile acid synthesis and metabolism","volume":"50","author":"Russell","year":"2009","journal-title":"J. Lipid Res."},{"key":"B41","doi-asserted-by":"publisher","first-page":"469","DOI":"10.5937\/hpimj,1701469S","article-title":"Biosynthesis and Biotransformation of Bile Acids","volume":"4","author":"Sarenac","year":"2017","journal-title":"Hosp. Pharmacol. Int. Multydiscip. J"},{"key":"B42","first-page":"389","article-title":"Pleiotropic functions of bile acids mediated by the farnesoid X receptor","volume":"75","author":"Stanimirov","year":"2012","journal-title":"Acta GastroEnterol. Belg."},{"key":"B43","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3109\/03602532.2012.748793","article-title":"Nuclear-receptor-mediated regulation of drug- and bile-acid-transporter proteins in gut and liver","volume":"45","author":"Staudinger","year":"2013","journal-title":"Drug Metab. Rev."},{"key":"B44","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1080\/21553769.2013.879925","article-title":"Application of bile acids in drug formulation and delivery","volume":"7","author":"Stojan\u010devi\u0107","year":"2013","journal-title":"Front. Life sci"},{"key":"B45","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1586\/17512433.2015.1092381","article-title":"Obeticholic acid for the treatment of primary biliary cirrhosis","volume":"9","author":"Trivedi","year":"2016","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"2948","DOI":"10.2337\/diacare.28.12.2948","article-title":"Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities","volume":"28","author":"Zammitt","year":"2005","journal-title":"Diabetes Care"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2018.00939\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T11:55:23Z","timestamp":1537876523000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2018.00939\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,25]]},"references-count":46,"alternative-id":["10.3389\/fphar.2018.00939"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2018.00939","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,25]]},"article-number":"939"}}